BLISSGVS vs KOPRAN: Stock Comparison

Bliss GVS Pharma Limited vs Kopran Limited

Live data: 2 July 2026, 4:08 PM IST • Source: NSE and company filings

Bliss GVS Pharma Limited is the larger company by market capitalisation. Bliss GVS Pharma Limited shows a lower P/E, faster revenue growth and a higher ROCE, while Kopran Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Bliss GVS Pharma Limited and Kopran Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BLISSGVS is more favourable on 9 of 13 scored metrics and KOPRAN on 4These counts are context-free and are not an overall rating.

Key Differences

Market Cap
BLISSGVS is the larger company
₹4,782 Cr vs ₹942 Cr
P/E Ratio
BLISSGVS has a lower P/E
38.27x vs 38.28x
P/B Ratio
KOPRAN has a lower P/B
1.86x vs 4.14x
EPS
BLISSGVS has higher earnings per share
₹11.99 vs ₹3.41
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 0.19%
Revenue Growth (TTM YoY)
BLISSGVS has faster revenue growth
29.8% vs -3.66%
EPS Growth (TTM YoY)
BLISSGVS has faster EPS growth
124.7% vs -71.88%
Qtr Sales Growth
BLISSGVS has stronger quarterly sales growth
13% vs -3.03%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBLISSGVSKOPRAN
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBLISSGVSKOPRAN
Live Price₹527.1₹206.27
Day Change0.68%6.56%
Volume3.93 L38.55 L
52-Week High₹553₹219
52-Week Low₹118₹107
Distance from 52W High-4.68%-5.81%

Valuation

MetricBLISSGVSKOPRAN
Market Cap₹4,782 Cr₹942 Cr
P/E Ratio38.27x38.28x
P/B Ratio4.14x1.86x
EPS₹11.99₹3.41
Book Value₹107.21₹107.35
Dividend Yield0.19%1.59%

Growth

MetricBLISSGVSKOPRAN
Revenue Growth (TTM YoY)29.8%-3.66%
EPS Growth (TTM YoY)124.7%-71.88%
Qtr Sales Growth13%-3.03%
Qtr Profit Growth108%-32.9%

Profitability & Leverage

MetricBLISSGVSKOPRAN
ROE0%4.85%
ROCE11.7%9.75%
Net Margin13.93%3.78%
Operating Margin12.82%6.58%
Debt to Equity1.77x0.29x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricBLISSGVSKOPRAN
Promoter Holding35.36%44.42%
FII Holding10.45% 4.09 pp0.51% 0.06 pp
DII Holding5.04% 0.74 pp0%
Public Holding49.15% 4.83 pp55.06% 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Bliss GVS Pharma Limited and Kopran Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.